Concert Pharmaceuticals logo
Concert Pharmaceuticals CNCE
report update icon

Quarterly report 2022-Q3
added 05-16-2026

Concert Pharmaceuticals General and Administrative Expenses | CNCE

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.
What these expenses include
  • Salaries of administrative staff (executives, HR, accountants, legal personnel)
  • Office rent and utilities
  • Office equipment and IT infrastructure
  • Professional services (auditors, lawyers, consultants)
  • Insurance
  • General administrative travel and representation expenses
What the metric indicates
  • Cost control
    A high level of such expenses may indicate inefficient management or an overly complex structure
  • Profitability
    Reducing administrative expenses while maintaining stable revenue increases operating profit
  • Comparative analysis
    Investors can compare this metric as a percentage of revenue among companies in the same industry
  • Business flexibility
    Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Concert Pharmaceuticals

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
22.5 M 18.9 M 20.3 M 22.9 M 21 M 14.4 M 13.1 M 11.7 M 8.03 M 7.27 M 7.38 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
22.9 M 7.27 M 15.2 M

Quarterly General and Administrative Expenses Concert Pharmaceuticals

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- 5.25 M 4.85 M 5.54 M - 5.46 M 5.61 M 5.48 M - 4.51 M 4.73 M 4.67 M - 4.74 M 4.98 M 5.61 M - 6.32 M 5.51 M 5.63 M - 4.88 M 5.71 M 5.25 M - 3.44 M 3.83 M 3.58 M - 3.27 M 3.3 M 3.23 M - 3.46 M 2.72 M 2.54 M - 2.13 M 2.27 M 1.96 M - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
6.32 M 1.96 M 4.35 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer General and Administrative Expenses Price % 24h Market Cap Country
Brickell Biotech Brickell Biotech
BBI
11.2 M - -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
56 M - - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
13.2 M - - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
37.8 M - - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
11.8 M - - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
82.8 M - - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
28.9 M - - $ 2.36 B usaUSA
Annexon Annexon
ANNX
31.7 M $ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
8.67 M - 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
13.4 M - -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
147 M - - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
497 K - -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
3.65 M - -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
3.64 M $ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
16.3 M $ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
10.9 M - 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
16.6 M - - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
19.8 M - -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
15.8 M - -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
15.6 M - - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
203 M - 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
259 M - -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
6.02 M - -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
12.2 M - -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
37.9 M - - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
150 M - - $ 69.7 B britainBritain
Atreca Atreca
BCEL
31.5 M - -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
7.48 M - -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
12.2 M - - $ 109 M usaUSA
Akouos Akouos
AKUS
22.2 M - 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
116 M - - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
10.1 M - -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
20.6 M - - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
7.98 M - - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
2 M - -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
7.96 M - -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
19.7 M - - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
11.2 M - 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
106 M - -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
69.6 M - -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
168 M - - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
10.7 M - 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
23.4 M - - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
12.2 M - -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
19 M - - $ 728 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
14.7 M - - $ 155 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
37.8 M - - $ 127 M usaUSA
Aravive Aravive
ARAV
13 M - -13.39 % $ 1.45 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
15.7 M - - $ 231 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
191 M $ 84.95 0.13 % $ 7.99 B usaUSA